Dr. Adebunmi (Bunmi) Urakpo serves as Vice President of Pharmacovigilance for AVEO Oncology, an LG Chem Company, bringing over 20 years of experience in drug safety and pharmacovigilance, clinical research, and public health.

Dr. Urakpo most recently served as a Pharmacovigilance and Drug Safety Consultant at NADDBio LLC (“NADDBio”), a clinical-stage R&D consultancy firm. Prior to joining NADDBio, Dr. Urakpo worked at PrimeVigilance Ltd. (“PrimeVigilance”), where she held positions of increasing responsibilities to eventually become the Senior Medical Director and the Head of Medical Operations. She also served as Interim Head of the Benefit Risk Department while at PrimeVigilance. Dr. Urakpo was an EU/UK Qualified Person for Pharmacovigilance (QPPV) for over eight years.

Dr. Urakpo holds a medical degree from the University of Ibadan (Nigeria), a master’s in public health from the University of Liverpool, a postgraduate diploma in pharmacovigilance from the University of Hertfordshire, and an MBA certification from the London School of Economics.